Omnio

Executive Summary

Omnio is a Swedish biotechnology company focused on regenerative therapies for chronic wounds, particularly diabetic foot ulcers (DFUs). Its lead candidate, recombinant plasminogen (Rec-PLG), is designed to restart the body's stalled natural healing process. The company is currently in the pre-clinical stage and aims to address a significant unmet medical need, as DFUs affect millions globally and have limited treatment options. Omnio's approach leverages a well-understood mechanism of action, potentially offering a novel solution for hard-to-heal wounds. While the company has not disclosed funding details or valuation, its focus on a high-need area positions it for potential partnerships or further investment as it advances toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND filing for Rec-PLG in diabetic foot ulcers60% success
• Q3 2026Preclinical proof-of-concept data publication70% success
• Q1 2027Series A funding or strategic partnership announcement50% success